Sharekhan recommended Hold rating on Aurobindo Pharma with a target price of Rs 710 in its research report dated August 08, 2019.
Sharekhan's research report on Aurobindo Pharma
Q1 numbers were strong; new products, better product mix and operational efficiencies led to robust profitability. Gross debt reduced by ~ Rs 1,084 crore to Rs. 5883.2 crore; net debt fell by Rs. 915 crore to Rs. 4,094 crore. Regulatory hurdles at various plants would weigh on stock until successful resolution.
We maintain a Hold rating with an unchanged PT of Rs. 710. We expect company to report sales and profit CAGRs of 29% and 22%,
respectively, in the next two years.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.LIVE NOW... Video series on How to Double Your Monthly Income... where Rahul Shah, Ex-Swiss Investment Banker and one of India's leading experts on wealth building, reveals his secret strategies for the first time ever. Register here to watch it for FREE.